Principal investigator and consultant Niklas Nielsen, noted for his pioneering work in clinical trials regarding the effects of cooling published in New England Journal of Medicine, has signed an agreement with Lytics for yet another large international multicenter clinical trial. The trial, TTM2, has due to the immense success of the previous trial received much attention.
Apart from facilitating all data capture with the Lytics SIF© technology for the trial there are also plans for incorporating and evaluating machine learning generated forecasts. Dr. Nielsen commented this part of the trial in the newspaper Helsingborgs Dagblad:
“The trial will also generate other profound knowledge. We can, for instance, learn more about forecasts and better determine when to reinforce medical treatment or when to interrupt critical care for the patient. When one question is answered there are usually 20 new ones.”
”We are very excited and proud to once again work with Dr. Nielsen and his team to bring more clarity about the impact of cooling on sudden cardiac arrest patients as well as investigating the opportunities for predictions in the clinical work”, said Mattias Paulsson, Partner and CEO of Lytics. The trial is planned to go live in the spring of 2017.